ENTA vs. ZVRA, GLUE, ANAB, ATXS, UPB, RGNX, AURA, TSHA, ORKA, and RVNC
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Zevra Therapeutics (ZVRA), Monte Rosa Therapeutics (GLUE), AnaptysBio (ANAB), Astria Therapeutics (ATXS), Upstream Bio (UPB), REGENXBIO (RGNX), Aura Biosciences (AURA), Taysha Gene Therapies (TSHA), Oruka Therapeutics (ORKA), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical products" industry.
Enanta Pharmaceuticals vs.
Enanta Pharmaceuticals (NASDAQ:ENTA) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.
Enanta Pharmaceuticals received 289 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 56.94% of users gave Enanta Pharmaceuticals an outperform vote.
Enanta Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 2, meaning that its share price is 100% more volatile than the S&P 500.
Enanta Pharmaceuticals has a net margin of -157.57% compared to Zevra Therapeutics' net margin of -342.63%. Enanta Pharmaceuticals' return on equity of -75.53% beat Zevra Therapeutics' return on equity.
Zevra Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Enanta Pharmaceuticals currently has a consensus price target of $17.25, suggesting a potential upside of 114.82%. Zevra Therapeutics has a consensus price target of $21.57, suggesting a potential upside of 180.88%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Enanta Pharmaceuticals.
95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 13.9% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Enanta Pharmaceuticals and Enanta Pharmaceuticals both had 5 articles in the media. Zevra Therapeutics' average media sentiment score of 0.37 beat Enanta Pharmaceuticals' score of -0.08 indicating that Zevra Therapeutics is being referred to more favorably in the news media.
Summary
Zevra Therapeutics beats Enanta Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ENTA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ENTA Stock Alerts